A distinct coagulopathy associated with interleukin-2 therapy.
We studied the coagulation profiles of 14 patients with advanced malignancies treated with Interleukin-2 (IL-2). A 43% prolongation of the PTT (P < 0.001) and a significant decrease in functional levels of factors II, IX, X, XI, and XII were observed 6 h post IL-2 treatment in comparison to pretreatment values. These parameters normalized within 2-3 d following IL-2 administration. The PT, factors V, VII, VIII, fibrinogen and D-dimer levels were unchanged with IL-2 treatment. This pattern of coagulopathy has not previously been reported.
Oleksowicz
L
L
Montefiore Medical Center, Bronx, New York 10467.
Strack
M
M
Dutcher
J P
JP
Sussman
I
I
Caliendo
G
G
Sparano
J
J
Wiernik
P H
PH
D001778:Blood Coagulation Disorders / Q000209:etiology*; D001779:Blood Coagulation Factors / Q000032:analysis; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D009369:Neoplasms / Q000097:blood / Q000628:therapy; D010314:Partial Thromboplastin Time; D011446:Prospective Studies
D001779:Blood Coagulation Factors; D007376:Interleukin-2